Quality of life, efficacy, and patient-reported outcome with NEPA as antiemetic prophylaxis in patients receiving highly or moderately emetogenic chemotherapy

被引：0
|
作者：
Karthaus, M. [1 ]
Rauh, J. [1 ]
Guth, D. [1 ]
Heilmann, V. [1 ]
Schilling, J. [1 ]
机构：
[1] Stadt Klinikum Munchen Harlaching, Klin Hamatol Onkol & Palliat Med, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1506TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
    Cesare Gridelli
    Amin M. Haiderali
    Mark W. Russo
    Linda M. Blackburn
    Konstantinos Lykopoulos
    Supportive Care in Cancer, 2010, 18 : 1437 - 1444
  • [22] Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy-a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines
    Yu, Shiying
    Burke, Thomas A.
    Chan, Alexandre
    Kim, Hoon-Kyo
    Hsieh, Ruey Kuen
    Hu, Xichun
    Liang, Jin-Tung
    Banos, Ana
    Spiteri, Carmel
    Keefe, Dorothy M. K.
    SUPPORTIVE CARE IN CANCER, 2015, 23 (01) : 273 - 282
  • [23] Quality of life, effectiveness and patient reported outcomes of antiemetic prophylaxis with NEPA within the German NIS AkyPRO: post-hoc analysis of patients receiving carboplatin-based chemotherapy
    Schilling, J.
    Lorenz, R.
    Rezek, D.
    Bauer, L.
    Hornung, D.
    Sattler, D.
    Ackermann, S.
    Karthaus, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (06) : E59 - E60
  • [24] Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment
    Bloechl-Daum, Brigitte
    Deuson, Robert R.
    Mavros, Panagiotis
    Hansen, Mogens
    Herrstedt, Jorn
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4472 - 4478
  • [25] Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy
    Abe, Masakazu
    Kasamatsu, Yuka
    Kado, Nobuhiro
    Kuji, Shiho
    Tanaka, Aki
    Takahashi, Nobutaka
    Takekuma, Munetaka
    Hirashima, Yasuyuki
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [26] COST-EFFECTIVENESS OF APREPITANT IN PATINENTS RECEIVING ANTIEMETIC PROPHYLAXIS FOR HIGHLY EMETOGENIC CHEMOTHERAPY IN HUNGARY
    Nagy, L.
    Erdesz, D.
    Lovas, K.
    Wisniewski, T.
    VALUE IN HEALTH, 2008, 11 (06) : A469 - A469
  • [27] Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
    Navari, Rudolph M.
    Rapoport, Bernardo L.
    Powers, Dan
    Arora, Sujata
    Clark-Snow, Rebecca
    CANCER MEDICINE, 2018, 7 (07): : 2943 - 2950
  • [28] Economic analysis of aprepitant in patients receiving antiemetic prophylaxis with moderately emetogenic chemotherapy in France - results of a decision-analytic model
    Pellissier, J.
    Briand, Y.
    Davies, G.
    Souchet, T.
    Deuson, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 370 - 370
  • [29] Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy
    Schwartzberg, L.
    Roeland, E.
    Andric, Z.
    Kowalski, D.
    Radic, J.
    Voisin, D.
    Rizzi, G.
    Navari, R.
    Gralla, R. J.
    Karthaus, M.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1535 - 1540
  • [30] Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy
    Coppes, MJ
    Lau, R
    Ingram, LC
    Wiernikowski, JT
    Grant, R
    Howard, DR
    Perrotta, M
    Barr, R
    Dempsey, E
    Greenberg, ML
    Leclerc, JM
    MEDICAL AND PEDIATRIC ONCOLOGY, 1999, 33 (02): : 99 - 105
12345